^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kaitanni (cadonilimab)

    i
    Company:
    Akesobio
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    Apply
    Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) (AK104-IIT-019) (NCT05587374)
    Phase 3
    Sun Yat-sen University
    Active, not recruiting
    Last update posted :
    01/23/2025
    Initiation :
    08/01/2023
    Primary completion :
    08/01/2027
    Completion :
    08/01/2029
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • gemcitabine • Kaitanni (cadonilimab)
    A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma (NCT06553781)
    Phase N/A
    Fudan University
    Not yet recruiting
    Last update posted :
    08/14/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    BRAF
    |
    Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)
    Disitamab Vedotin (RC48) in Combination With AK104 (PD-1/CTLA-4 Bispecific) and Bevacizumab for the Treatment of Recurrent and Persistent Clear Cell Ovarian Cancer: a Single-arm, Phase II, Multicenter Study (DAB OCC Study) (NCT06540729)
    Phase 2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Not yet recruiting
    Last update posted :
    08/06/2024
    Initiation :
    07/31/2024
    Primary completion :
    08/01/2028
    Completion :
    08/01/2030
    MSI
    |
    Avastin (bevacizumab) • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma (NCT06532539)
    Phase 2
    Shandong Cancer Hospital and Institute
    Recruiting
    Last update posted :
    08/01/2024
    Initiation :
    06/13/2024
    Primary completion :
    05/01/2025
    Completion :
    05/01/2026
    CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR
    |
    cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)
    A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer (NCT05505825)
    Phase 1/2
    Akeso
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    08/26/2022
    Primary completion :
    12/01/2024
    Completion :
    01/01/2025
    ATRX
    |
    ATRX mutation
    |
    Kaitanni (cadonilimab) • Auraza (chiauranib)
    A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT04647344)
    Phase 1/2
    Akeso
    Completed
    Last update posted :
    04/25/2024
    Initiation :
    11/24/2020
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    EGFR • ALK
    |
    EGFR wild-type
    |
    carboplatin • paclitaxel • pemetrexed • Kaitanni (cadonilimab)
    To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) (NCT06341660)
    Phase 2
    Guangzhou Institute of Respiratory Disease
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    05/25/2023
    Primary completion :
    06/01/2025
    Completion :
    07/01/2025
    STK11
    |
    Kaitanni (cadonilimab)
    A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NCT06331650)
    Phase 2
    Guangzhou Institute of Respiratory Disease
    Recruiting
    Last update posted :
    03/26/2024
    Initiation :
    08/09/2023
    Primary completion :
    08/01/2025
    Completion :
    10/01/2025
    STK11
    |
    Kaitanni (cadonilimab)
    Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (NCT06143748)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    03/12/2024
    Initiation :
    03/02/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2027
    CD8 • CTLA4 • NCAM1 • CD68
    |
    cisplatin • paclitaxel • Kaitanni (cadonilimab)
    Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer (NCT06289751)
    Phase 2
    Tongji Hospital
    Not yet recruiting
    Last update posted :
    03/04/2024
    Initiation :
    03/01/2024
    Primary completion :
    03/01/2026
    Completion :
    01/01/2031
    PD-L1
    |
    cisplatin • paclitaxel • Kaitanni (cadonilimab)
    Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer (NCT05980689)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    10/24/2023
    Primary completion :
    06/30/2024
    Completion :
    01/31/2025
    MSI
    |
    capecitabine • Kaitanni (cadonilimab)
    Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases (CBC) (NCT05812534)
    Phase 2
    Second Affiliated Hospital of Nanchang University
    Not yet recruiting
    Last update posted :
    11/18/2023
    Initiation :
    12/01/2023
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    EGFR
    |
    ALK negative
    |
    Avastin (bevacizumab) • carboplatin • Kaitanni (cadonilimab)
    Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer (NCT05839470)
    Phase 2
    Fujian Cancer Hospital
    Recruiting
    Last update posted :
    11/15/2023
    Initiation :
    11/19/2023
    Primary completion :
    03/01/2024
    Completion :
    03/01/2025
    MSI
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Kaitanni (cadonilimab) • levoleucovorin calcium
    Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance (NCT06118645)
    Phase 2
    China Medical University, China
    Not yet recruiting
    Last update posted :
    11/06/2023
    Initiation :
    11/01/2023
    Primary completion :
    09/01/2024
    Completion :
    08/01/2026
    PD-L1
    |
    paclitaxel • Kaitanni (cadonilimab)
    A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer (NCT06074484)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    10/10/2023
    Initiation :
    09/10/2023
    Primary completion :
    08/10/2024
    Completion :
    08/10/2025
    HER-2
    |
    HER-2 expression
    |
    Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma (NCT05808608)
    Phase 1/2
    Hao Zeng
    Not yet recruiting
    Last update posted :
    09/25/2023
    Initiation :
    09/01/2023
    Primary completion :
    10/01/2025
    Completion :
    12/01/2025
    TFE3
    |
    Inlyta (axitinib) • Kaitanni (cadonilimab)
    Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC) (NCT06023875)
    Phase 2
    Xuekui Liu
    Recruiting
    Last update posted :
    09/05/2023
    Initiation :
    07/19/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PD-L1
    |
    cisplatin • docetaxel • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ACHELOUS) (NCT06001151)
    Phase 2
    Qian Chu
    Recruiting
    Last update posted :
    08/21/2023
    Initiation :
    08/07/2023
    Primary completion :
    08/31/2025
    Completion :
    08/31/2027
    EGFR • PD-L1 • ALK • ROS1
    |
    EGFR L858R • ALK rearrangement • ROS1 fusion
    |
    carboplatin • pemetrexed • Kaitanni (cadonilimab)
    Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody (NCT05994001)
    Phase 1/2
    Shanghai Zhongshan Hospital
    Recruiting
    Last update posted :
    08/16/2023
    Initiation :
    08/01/2023
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    CLDN18 • PD-1 • CTLA4
    |
    Kaitanni (cadonilimab)
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NCT05990127)
    Phase 3
    Akeso
    Not yet recruiting
    Last update posted :
    08/14/2023
    Initiation :
    11/14/2023
    Primary completion :
    08/05/2025
    Completion :
    11/28/2026
    PD-L1
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Kaitanni (cadonilimab)
    Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NCT05947201)
    Phase 2
    Weijia Fang, MD
    Recruiting
    Last update posted :
    08/08/2023
    Initiation :
    05/08/2023
    Primary completion :
    03/01/2024
    Completion :
    10/01/2024
    PD-L1
    |
    cisplatin • 5-fluorouracil • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (NCT05913570)
    Phase 2
    LiuYing
    Not yet recruiting
    Last update posted :
    06/22/2023
    Initiation :
    06/20/2023
    Primary completion :
    12/20/2023
    Completion :
    12/20/2023
    MSI • PD-1 • CTLA4
    |
    MSI-H/dMMR
    |
    Kaitanni (cadonilimab)
    Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T (NCT05886257)
    Phase 2
    Shi Ming
    Withdrawn
    Last update posted :
    06/02/2023
    Initiation :
    12/07/2022
    Primary completion :
    03/31/2023
    Completion :
    03/31/2023
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Kaitanni (cadonilimab)
    Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors (NCT05824494)
    Phase 2
    Women's Hospital School Of Medicine Zhejiang Un...
    Not yet recruiting
    Last update posted :
    05/05/2023
    Initiation :
    06/01/2023
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    PD-L1
    |
    albumin-bound paclitaxel • Kaitanni (cadonilimab)
    Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018) (NCT05816499)
    Phase 1/2
    Shanghai Chest Hospital
    Recruiting
    Last update posted :
    04/17/2023
    Initiation :
    02/16/2023
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion
    |
    docetaxel • Focus V (anlotinib) • Kaitanni (cadonilimab)
    Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T (NCT05760599)
    Phase 2
    Shi Ming
    Recruiting
    Last update posted :
    03/08/2023
    Initiation :
    02/27/2023
    Primary completion :
    01/01/2024
    Completion :
    07/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Kaitanni (cadonilimab)
    Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer (CSWOG-C03) (NCT05426005)
    Phase 1/2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    02/09/2023
    Initiation :
    02/07/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2027
    PD-L1 • MSI
    |
    MSI-H/dMMR
    |
    Kaitanni (cadonilimab)
    AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC (AK104-IIT-014) (NCT05522894)
    Phase 2
    Chinese Academy of Medical Sciences
    Not yet recruiting
    Last update posted :
    08/31/2022
    Initiation :
    10/01/2022
    Primary completion :
    04/01/2024
    Completion :
    10/01/2024
    PD-L1
    |
    cisplatin • paclitaxel • Kaitanni (cadonilimab)
    AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer (NCT04556253)
    Phase 2
    Peking University
    Not yet recruiting
    Last update posted :
    09/21/2020
    Initiation :
    10/01/2020
    Primary completion :
    10/01/2022
    Completion :
    10/01/2023
    MSI
    |
    MSI-H/dMMR
    |
    Kaitanni (cadonilimab)
    A Study of Combination Therapy in NSCLC (NCT04544644)
    Phase 2
    Chinese PLA General Hospital
    Not yet recruiting
    Last update posted :
    09/10/2020
    Initiation :
    09/01/2020
    Primary completion :
    09/01/2022
    Completion :
    09/01/2023
    PD-L1
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)